Dapagliflozin in Active Lupus Nephritis
Sodium-Glucose Co-Transporter-2 Inhibitors in Lupus Nephritis
Brigham and Women's Hospital
33 participants
May 19, 2026
INTERVENTIONAL
Conditions
Summary
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Pilot and feasibility of adding dapagliflozin to standard medical therapy in active lupus nephritis (LN)
Matching placebo daily with standard of care
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07323524